Terms: = Lung cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Prognosis
616 results:
1. CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-pd-1 immunotherapy.
Qu J; Wu B; Chen L; Wen Z; Fang L; Zheng J; Shen Q; Heng J; Zhou J; Zhou J
J Exp Clin Cancer Res; 2024 May; 43(1):134. PubMed ID: 38698468
[TBL] [Abstract] [Full Text] [Related]
2. Prediction of Responsiveness to PD-L1/pd-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in lung Adenocarcinoma and Squamous Cell Carcinoma.
Koh YW; Han JH; Haam S; Lee HW
Anticancer Res; 2024 May; 44(5):2081-2089. PubMed ID: 38677736
[TBL] [Abstract] [Full Text] [Related]
3. Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.
Han R; Guo H; Shi J; Zhao S; Jia Y; Liu X; Liu Y; Cheng L; Zhao C; Li X; Zhou C
BMC Med; 2024 Apr; 22(1):174. PubMed ID: 38658988
[TBL] [Abstract] [Full Text] [Related]
4. Peripheral CD4
Yang X; Li Q; Zeng T
Front Immunol; 2024; 15():1364507. PubMed ID: 38650951
[TBL] [Abstract] [Full Text] [Related]
5. Association of metabolomics with pd-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer.
Zheng L; Hu F; Huang L; Lu J; Yang X; Xu J; Wang S; Shen Y; Zhong R; Chu T; Zhang W; Li Y; Zheng X; Han B; Zhong H; Nie W; Zhang X
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38641349
[TBL] [Abstract] [Full Text] [Related]
6. Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy.
Brun SS; Hansen TF; Wen SWC; Nyhus CH; Bertelsen L; Jakobsen A; Hansen TS; Nederby L
Sci Rep; 2024 Apr; 14(1):8993. PubMed ID: 38637655
[TBL] [Abstract] [Full Text] [Related]
7. Predictive Value of NLR and PLR in Driver-Gene-Negative Advanced Non-Small Cell lung cancer Treated with pd-1/PD-L1 Inhibitors: A Single Institutional Cohort Study.
Yuan Q; Xu C; Wang W; Zhang Q
Technol Cancer Res Treat; 2024; 23():15330338241246651. PubMed ID: 38613344
[TBL] [Abstract] [Full Text] [Related]
8. Radiotherapy combined with anti-pd-1 and TKI for primary cardiac angiosarcoma considering the joint assessment of TLSs and PD-L1: a case report.
Deng S; Yang X; He L; Zhang Q; Zhao C; Meng H
J Cardiothorac Surg; 2024 Apr; 19(1):194. PubMed ID: 38594687
[TBL] [Abstract] [Full Text] [Related]
9. Tanshinone IIA induces ER stress and JNK activation to inhibit tumor growth and enhance anti-pd-1 immunotherapy in non-small cell lung cancer.
Zhang YZ; Lai HL; Huang C; Jiang ZB; Yan HX; Wang XR; Xie C; Huang JM; Ren WK; Li JX; Zhai ZR; Yao XJ; Wu QB; Leung EL
Phytomedicine; 2024 Jun; 128():155431. PubMed ID: 38537440
[TBL] [Abstract] [Full Text] [Related]
10. Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in
Pillai R; LeBoeuf SE; Hao Y; New C; Blum JLE; Rashidfarrokhi A; Huang SM; Bahamon C; Wu WL; Karadal-Ferrena B; Herrera A; Ivanova E; Cross M; Bossowski JP; Ding H; Hayashi M; Rajalingam S; Karakousi T; Sayin VI; Khanna KM; Wong KK; Wild R; Tsirigos A; Poirier JT; Rudin CM; Davidson SM; Koralov SB; Papagiannakopoulos T
Sci Adv; 2024 Mar; 10(13):eadm9859. PubMed ID: 38536921
[TBL] [Abstract] [Full Text] [Related]
11. Inhibition of PD-L1 expression in non-small cell lung cancer may reduce vasculogenic mimicry formation by inhibiting the epithelial mesenchymal transformation process.
Shi Y; Li W; Jia Q; Wu J; Wu S; Wu S
Exp Cell Res; 2024 Apr; 437(1):113996. PubMed ID: 38508327
[TBL] [Abstract] [Full Text] [Related]
12. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
13. [Improved Outcomes in Resectable Advanced or Recurrent lung cancer].
Goto Y
Gan To Kagaku Ryoho; 2024 Mar; 51(3):237-239. PubMed ID: 38494799
[TBL] [Abstract] [Full Text] [Related]
14. [Interest of focal radiotherapy in case of oligoprogression under immunotherapy in the treatment of metastatic non-small cell lung cancer].
Gagé A; Pereira B; Belliere A; Janicot H; Jeannin G; Bourrachot C; Durand M; Rolland-Debord C; Merle P
Bull Cancer; 2023 Dec; 110(12):1234-1243. PubMed ID: 38445648
[TBL] [Abstract] [Full Text] [Related]
15. Molecular classification reveals the sensitivity of lung adenocarcinoma to radiotherapy and immunotherapy: multi-omics clustering based on similarity network fusion.
Zhang J; Li Y; Dai W; Tang F; Wang L; Wang Z; Li S; Ji Q; Zhang J; Liao Z; Yu J; Xu Y; Gong J; Hu J; Li J; Guo X; He F; Han L; Gong Y; Ouyang W; Wang Z; Xie C
Cancer Immunol Immunother; 2024 Mar; 73(4):71. PubMed ID: 38430394
[TBL] [Abstract] [Full Text] [Related]
16. STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Baptiste Oudart J; Garinet S; Leger C; Barlesi F; Mazières J; Jeannin G; Audigier-Valette C; Morot-Sibilot D; Langlais A; Amour E; Mathiot N; Birsen G; Blons H; Wislez M
Lung Cancer; 2024 Apr; 190():107508. PubMed ID: 38428265
[TBL] [Abstract] [Full Text] [Related]
17. Role of immune checkpoint inhibitors combined with chemotherapy in recurrent drug-resistant gestational trophoblastic neoplasia: Four case reports and literature review.
Liu W; Zhu Y; Wang Y; Li R; Zou D; Chen R; Yang L; Huang Y
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2016. PubMed ID: 38425251
[TBL] [Abstract] [Full Text] [Related]
18. cancer-associated Fibroblast-specific Expression of the Matricellular Protein CCN1 Coordinates Neovascularization and Stroma Deposition in Melanoma Metastasis.
Hutchenreuther J; Nguyen J; Quesnel K; Vincent KM; Petitjean L; Bourgeois S; Boyd M; Bou-Gharios G; Postovit LM; Leask A
Cancer Res Commun; 2024 Feb; 4(2):556-570. PubMed ID: 38363129
[TBL] [Abstract] [Full Text] [Related]
19. Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051.
Miura K; Yamaguchi O; Mori K; Nakamura A; Tamiya M; Oba T; Yanagitani N; Mizutani H; Ninomiya T; Kajiwara T; Ito K; Miyanaga A; Arai D; Kodama H; Kobayashi K; Kaira K
Sci Rep; 2024 Feb; 14(1):3816. PubMed ID: 38360906
[TBL] [Abstract] [Full Text] [Related]
20. Rab37 mediates trafficking and membrane presentation of pd-1 to sustain T cell exhaustion in lung cancer.
Kuo WT; Kuo IY; Hsieh HC; Wu ST; Su WC; Wang YC
J Biomed Sci; 2024 Feb; 31(1):20. PubMed ID: 38321486
[TBL] [Abstract] [Full Text] [Related]
[Next]
